Skip to main content

Advertisement

Table 5 HbA1c-levels as a function of the duration of diabetes

From: Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study

Medication classification Duration of diabetes classification n Baseline maen ± SD After administration mean ± SD Difference mean ± SD
All cases Total 1464 8.44 ± 1.34 7.76 ± 1.29 -0.68 ± 1.34 §  
  < 1 year 70 8.65 ± 1.63 7.04 ± 1.08 -1.60 ± 1.82 § p = 0.002
  1-5 years 503 8.38 ± 1.35 7.69 ± 1.38 -0.69 ± 1.50 §  
  5-10 years 432 8.37 ± 1.25 7.81 ± 1.22 -0.56 ± 1.02 §  
  ≥ 10 years 459 8.56 ± 1.36 7.90 ± 1.25 -0.66 ± 1.27 §  
Diabetes drug use Subtotal 147 7.81 ± 0.95 7.33 ± 1.05 -0.47 ± 1.00 §  
Before study: not taken
&
< 1 year 14 7.72 ± 0.89 6.52 ± 0.75 -1.20 ± 1.31 ‡ p = 0.012
During study: not taken 1-5 years 75 7.73 ± 0.78 7.45 ± 1.08 -0.28 ± 0.88 ‡  
  5-10 years 38 7.85 ± 1.15 7.38 ± 1.13 -0.47 ± 0.97 ‡  
  ≥ 10 years 20 8.06 ± 1.16 7.36 ± 0.76 -0.70 ± 1,04 ‡  
  1. Baseline HBA1c levels for 1464 patients were ≥ 7.0%. P values were determined by ANOVA to assess statistically difference among duration of diabetes-subgroup